AstraZeneca (LON:AZN) Price Target Raised to GBX 74 at Jefferies Financial Group

AstraZeneca (LON:AZN) had its target price boosted by Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a report issued on Tuesday, MarketBeat reports. They currently have a hold rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently weighed in on AZN. Shore Capital reiterated a buy rating on shares of AstraZeneca in a report on Tuesday, May 21st. Deutsche Bank Aktiengesellschaft restated a hold rating and set a £110 ($139.13) price objective on shares of AstraZeneca in a research note on Tuesday, June 18th. Barclays restated an overweight rating and set a £125 ($158.11) price objective on shares of AstraZeneca in a research note on Monday, April 8th. Berenberg Bank upped their price objective on AstraZeneca from £130 ($164.43) to £150 ($189.73) and gave the stock a buy rating in a research note on Friday, June 7th. Finally, Citigroup restated a buy rating on shares of AstraZeneca in a research note on Tuesday, May 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of £105.53 ($133.49).

AstraZeneca Price Performance

AZN stock opened at £120.86 ($152.87) on Tuesday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 92.51. AstraZeneca has a 52-week low of GBX 9,461 ($119.67) and a 52-week high of £127.04 ($160.69). The stock’s 50 day moving average is £122.52 and its two-hundred day moving average is £110.93. The company has a market capitalization of £187.33 billion, a PE ratio of 3,873.72, a P/E/G ratio of 0.97 and a beta of 0.16.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.